Michigan cancer institute to deploy Eclipsys clinical, revenue cycle suite

The Barbara Ann Karmanos Cancer Institute in Detroit has signed an agreement to deploy Eclipsys’ Sunrise Enterprise integrated suite of clinical and revenue cycle applications.

The program, which includes use of Eclipsys’ IT outsourcing services for managing applications support, network management and help desk activities, as well as server and desktop computing, according to the Atlanta-based Eclipsys.

The cancer institute will implement Eclipsys’ RIS and Sunrise Record Manager, which will facilitate chart tracking and requests, chart completion, release of information, electronic signature and medical record abstracting.

In addition to automating its acute-care environments, Karmanos selected Sunrise Ambulatory Care to automate care delivery in its outpatient treatment centers, enabling a single integrated patient health record that will give clinicians access to the patient’s history of treatment and conditions, according to Eclipsys.

In terms of financial workflow enhancement, Karmanos said it will deploy Eclipsys’ revenue cycle management application for scheduling, registration, and follow-up billing processes with Sunrise Access Manager and Sunrise Patient Financials. 

As part of the agreement, Eclipsys will provide additional staff to manage the IT infrastructure across its facilities. As part of the IT outsourcing agreement, Karmanos said its IT employees will become employees of Eclipsys.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.